Business-focused practical solutions provided by a broad-gauged, business savvy lawyer with executive level in-house experience who understands your perspective, pressures and needs.
John Harre concentrates his practice on life sciences, agtech, technology and energy where he assists clients in the negotiation and drafting of licensing agreements, strategic collaborations and other complex transactional matters and advises them on business matters involving intellectual property issues, including mergers and acquisitions, investments and litigation. John primarily works with clients in the biotechnology, pharmaceuticals and medical devices industries, drawing on over 30 years of experience that includes private practice at several top-tier law firms and over a decade of executive in-house counsel and other leadership roles. John is also a licensed patent attorney.
University of Tennessee, M.S., Biotechnology, 1989
University of Missouri, B.A., Biology, 1986
Bar and Court Admissions
BAR ADMISSIONS
Massachusetts
Texas
U.S. Patent & Trademark Office
Experience
Complex Transactions
Concerto Biosciences, a microbial ecology company in a development and commercialization agreement with Sacco System, a global biotechnology company specializing in the research, development and production of natural and innovative biotechnological solutions for the food, nutraceutical, pharmaceutical, and agro-veterinary industries. The strategic agreement will allow Sacco to apply Concerto’s full stack data generation and AI platform, including its kChip technology and kAI model, to Sacco’s library of food-grade cultures to advance cutting-edge microbial ingredient discovery.
LigaChem Biosciences (KRX: 141080), a clinical stage biopharmaceutical company in a license agreement with Trican Biotechnology in which LigaChem will advance its proprietary pipeline of antibody-drug conjugate using antibodies generated by Trican
Daewoong Pharmaceutical (KRX: 069620) in its exclusive licensing agreement with CS Pharmaceuticals for a first-in-class PRS inhibitor `Bersiporocin' in Greater China
Ginkgo Bioworks (NYSE: DNA), a leading synthetic biology company, n various transactions, including:
Pfizer (NYSE: PFE) licensing agreement focused on the discovery of RNA-based drug candidates for up to $331 million in upfront, research, and development and commercial milestone payments, plus royalties, across three program
Merck (NYSE: MRK) licensing agreement to improve production efficiency and increase yields in biologic manufacturing for up to $490 million in upfront research fees, research milestone fees, option license payments and commercial milestone payments
its acquisition of StrideBio’s adeno-associated virus (AAV) capsid discovery and engineering platform assets
H.I.G. BioHealth Partners and Accelmed Partners as new investors and co-leads in the $52 million upsized Series B financing of digital therapeutics company Click Therapeutics
AffaMed Therapeutics, a global clinical stage biopharmaceutical company, in its strategic collaboration agreement with leading digital therapeutics company Beijing Infinite Brain Technologies to promote the application and development of digital therapy in neurological disorders
Jana Care in a collaboration agreement with Roche Diagnostics to develop and distribute Jana Care's point-of-care blood testing platform for chronic kidney disease and congestive heart failure
Peptron in a collaboration, license and manufacturing agreement with Invex Therapeutics for PresendinTM for the treatment of idiopathic intracranial hypertension
Yield10, in a Strategic Collaboration Agreement and Exclusive Option Agreement with Rothamsted Research to develop omega-3 oils in Camelina sativa
Large biotech in a Research and Exclusive Option Agreement and Asset Purchase Agreement with a biotech start-up
New Equilibrium Biosciences, in an Exclusive License Agreement with St. Jude Children’s Research Hospital
Intarcia Therapeutics in numerous collaboration and strategic agreements, including:
a Strategic Research Collaboration with California Institute for Biomedical Research for the development of stapled-peptide therapeutics
a Strategic Collaboration Agreement with Numab AG for the development of mono- and multi-specific antibodies for the treatment of diabetes, obesity and autoimmune indications
Archemix Corp. in numerous collaboration and strategic agreements, including:
a $285 million Asset Purchase and License Agreement with Baxter International Inc., Baxter Healthcare Corp., and Baxter Healthcare S.A for Archemix’ Hemophilia and Hemostasis Program
a Research Collaboration and Option Agreement with Dicerna Pharmaceuticals, Inc. for the development of aptamer-Dicer Substrate (DsiRNA) therapeutics for the treatment of various diseases
a $1.4 billion Research and Development Collaboration, Option and License Agreement with Glaxo Group Ltd. for the development of therapeutics for the treatment of inflammatory diseases
a Feasibility Study, License and Option Agreement with Eli Lilly and Company
a $245 million Collaborative Research and License Agreement with Takeda Pharmaceutical Company Ltd. for the development of aptamer therapeutics for various diseases
a $580M Collaborative Research and License Agreement with Merck KGaA for the development of aptamer therapeutics for oncology, inflammation and autoimmune diseases
a Collaborative Research, Services and License Agreement with Pfizer, Inc. for the development of aptamer therapeutics for various diseases
a $680 million Collaborative Research and License Agreement with Elan Pharma International for the development of aptamer therapeutics for various diseases
Intellectual Property
Established, built and managed intellectual property function at Archemix Corp. and Intarcia Therapeutics.
Developed, implemented and managed global patent filing and prosecution strategies at Archemix Corp. and Intarcia Therapeutics
Secured the issuance of modality (aptamer) wide medical use claims by EPO
Developed trademark acquisition strategy and managed trademark portfolio at Intarcia Therapeutics
Successfully petitioned for reversal of the rejection of Intarcia Therapeutics’ Proprietary Name Request
Lead intellectual property attorney in a multi-patent patent/antitrust suit
* Mr. Harre handled some of the above representations prior to joining Foley Hoag
PROFESSIONAL EXPERIENCE
Intarcia Therapeutics, Inc., Vice President Intellectual Property
Archemix Corp., Vice President, General Counsel and Business Development; Vice President, General Counsel; Vice President, Intellectual Property
Honors & Involvement
INVOLVEMENT
Member, American Intellectual Property Law Association
Member, Dean's Advisory Council, UNH Franklin Pierce School of Law
Co-chair, Legal Working Group, Massachusetts Biotechnology Council
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
